IND (Investigational New Drug)

1. lut 28, 2025

What Does the 'IND (Investigational New Drug)’ Mean?

An IND, or Investigational New Drug, refers to a new drug, biologic, or device that has not yet been approved by the FDA for marketing and distribution. It is a regulatory filing that allows pharmaceutical companies to ship and test an experimental drug in human clinical trials. The IND application includes preclinical data, manufacturing information, and protocols for proposed human studies.

Once the FDA approves an IND application, the sponsor can begin clinical trials to evaluate the drug’s safety and efficacy in humans. The IND process is a crucial step in drug development, bridging the gap between preclinical research and clinical testing. It ensures that potential new treatments are thoroughly evaluated for safety before being administered to human subjects.

Why Is the 'IND (Investigational New Drug)’ Important in Clinical Research?

The IND term is crucial in clinical research as it marks the transition from preclinical studies to human trials. It signifies that a drug candidate has met the necessary safety and quality standards to begin testing in humans, which is a critical milestone in the drug development process.

Understanding the IND process is essential for researchers, sponsors, and regulatory professionals involved in clinical trials. It helps ensure compliance with FDA regulations, protects the safety of trial participants, and provides a framework for the systematic evaluation of new drugs before they can be considered for market approval.

Good Practices and Procedures

1. Conduct thorough pre-IND meetings with the FDA to discuss study design, endpoints, and potential concerns before submission
2. Implement a robust pharmacovigilance system to monitor and report adverse events throughout the clinical trial process
3. Develop a comprehensive Chemistry, Manufacturing, and Controls (CMC) section, detailing drug substance and product specifications, stability data, and manufacturing processes
4. Establish clear communication channels between sponsors, contract research organizations (CROs), and clinical investigators to ensure timely updates and protocol adherence
5. Prepare contingency plans for potential clinical holds, including strategies for addressing FDA concerns and resuming trials efficiently

Related Terms

• Training Compliance
• Primary Endpoint
• Deviation Management